Navigation Links
Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
Date:3/23/2009

SAN DIEGO, March 23 /PRNewswire/ -- Nereus Pharmaceuticals, Inc., a pioneer in drug discovery from marine microbial sources, today announced that it is conducting a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) NPI-2358 in combination with standard chemotherapy (docetaxel) in patients with non-small cell lung cancer (NSCLC). This study follows on positive outcomes in the Phase 1 study assessing the safety, pharmacokinetics and efficacy of the combination.

Preclinical and clinical data suggest that VDAs may be complementary or synergistic with chemotherapeutics and anti-angiogenesis agents due to the different targets and mechanisms of action. In addition, the non-overlapping side effect profile of VDAs compared to most other anti-cancer treatments makes them ideal candidates to employ in new combination therapies. Models combining NPI-2358 with docetaxel have produced particularly positive results in both efficacy and tolerability.

The ADVANCE (Assessment of Docetaxel and Vascular Disruption in Non-Small Cell Lung Cancer) trial will assess NPI-2358 in combination with docetaxel compared to docetaxel alone in patients with NSCLC who previously failed at least one chemotherapy regimen. Overall survival will be the primary endpoint of the trial, and progression free survival and tumor response rates will be compared as secondary endpoints. Approximately 150 patients will participate in the trial at clinical trial sites in the U.S., Australia, India, and South America.

"This is an exciting time, as positive results for the combination of NPI-2358 and docetaxel appear to be translating well from the bench to the bedside. We will now be able to test the improvement in efficacy with the addition of NPI-2358 to the standard of care," said Dr. Shirish Gadgeel, M.D., Assistant Professor at the Barbara Ann Karmanos Cancer Institute in Detroit, Michigan where the first patient to
'/>"/>

SOURCE Nereus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...EW YORK, Dec. 2 Reportlinker.com a...lable in its catalogue: ,, Drug Discovery Tech...Opportunities ,, http://www.reportlinker.com/...date-of-Market-Trends--Opportunities.html ,, D...lement of every pharmaceutical company,s business ...
(Date:12/2/2009)...BREVILLE, Gabon, December 2 ,...e,s Problem and Heritage" , Coinciding wi...e 2010 the,Gabonese Republic is hosting an interna...ue of safeguarding biological resources in Africa.... state leaders, ministers,scientific experts, pri...
(Date:12/2/2009)...RESTON, Va., Dec. 2 /PRNewswire-Asia-FirstCall/ --...any") (OTC Bulletin Board: EMDY), a leading,produc...a, milk powder and,soybean products in China, toda...he Spring issue of US Food & Drink Executive, ...,000 executives in the food and beverage industry....
(Date:12/2/2009)...N, N.J., Dec. 2 According to the N...ent of Americans diagnosed with diabetes already h...retinopathy, damage to the retina caused by leaky ...ople with diabetes and is one of the most feared d...of all patients who,ve had diabetes for 10 years o...
Breaking Biology Technology:Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Libreville International Conference 2-3 June 2010 2Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4
...ikins, Ltd. published a FluForecast® warning i... and California H1N1 cases. The company was able ... its patented Replikin Count™ genomics techn...nes which have been linked with past epidemics.,Th...shed on the Web, stated that in H1N1 the company h...
...Results on Thursday, April 30, 2009 and Host Call ...l 24 Osteotech, Inc. (Nasdaq: OSTE ), a leader ...enerative healing, announced today that the Compan...esults will be released Thursday, April 30, 2009. ...rence call and webcast on Friday, May 1, 2009, at ...
...24 Sinobiopharma, Inc. (OTC Bulletin Board: SNBP)... report financial highlights from the unaudited fi...bruary 28, 2009. , , Financial highlights include...S $2,715,702 for the nine months ended February 28...riod ended February 29, 2008. , Gross profi...
Other Biology Technology:Biotechnology Company Provided Advance Warning of Mexican H1N1 "Swine Flu" Virus Outbreak 2Biotechnology Company Provided Advance Warning of Mexican H1N1 "Swine Flu" Virus Outbreak 3Biotechnology Company Provided Advance Warning of Mexican H1N1 "Swine Flu" Virus Outbreak 4Osteotech Announces First Quarter 2009 Earnings Release and Conference Call 2Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009 2
(Date:12/3/2009)...llers must be included in the design of the upcomi...umanitarian crisis, according to a scientist at th...re , Dr Simon Lewis argues that at least 50% of th...n, known as REDD (Reducing Emissions from Deforest...wellers directly, and their property rights assure...
(Date:12/3/2009)... A team of scientists from the U.S. Department of ...vard University, and the Indian Institute of Scien...cules locate the genetic information in DNA that i...esses. The research, published in the December 1, ...logy , confirms that many proteins responsible for...
(Date:12/2/2009)...ELPHIA Less acculturated Latino men have a more d...more acculturated to U.S. culture, but acculturati...ng. Details of these findings are published in Ca...rnal of the American Association for Cancer Resear...cco. , "Acculturation affects smoking cessation ...
Breaking Biology News(10 mins):Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Grooving down the helix 2Grooving down the helix 3Acculturation affects smoking cessation success among Latinos 2Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment at Major Danish Hospital 49187 1Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment at Major Danish Hospital 49187 2Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment at Major Danish Hospital 49187 3Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle free Symphony 28TM 29 Transdermal Continuous Glucose Monitoring Syste 49185 1Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle free Symphony 28TM 29 Transdermal Continuous Glucose Monitoring Syste 49185 2Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle free Symphony 28TM 29 Transdermal Continuous Glucose Monitoring Syste 49185 3Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle free Symphony 28TM 29 Transdermal Continuous Glucose Monitoring Syste 49185 4Arena Pharmaceuticals to Receive 24100 Million from Deerfield Management 49183 1Arena Pharmaceuticals to Receive 24100 Million from Deerfield Management 49183 2Arena Pharmaceuticals to Receive 24100 Million from Deerfield Management 49183 3Arena Pharmaceuticals to Receive 24100 Million from Deerfield Management 49183 4
...he largest scientific conference devoted primarily...gkok with a special session focused on four key to...yrus Cooper, Director of the MRC Epidemiology Reso...Norman Collisson Chair of Musculoskeletal Sciences...velopmental origins of osteoporosis. , He will out...
...) Transfusion science, a discipline of biomedi... diseases associated with blood transfusion and ti...s in recent years. The second edition of an infor...was recently released by Scion Publishing (www.sci...usion Science appeared in 1999. At that time, "[...
... that developed a successful insect pest managemen...nt pesticide reduction, will be honored at the Ent..., Nov. 16-19 in Reno. , The seven-member Almond P... (IPM) Team will receive the Entomological Foundat...y night, Nov. 16 in the Reno-Sparks Convention Cen...
Other Biology News:Nutrition and bone health session to open the IOF World Congress on Osteoporosis in Bangkok 2New book includes advances in the science and practice of transfusion and transplantation 2Almond pest management team to receive major award at ESA meeting 2
...provides maximum performance on minimum space. Tha...heating and cooling rates have been achieved that,...ty of 48 x 0.2ml tubes, the Tpersonal provides hal...ruments. Alternatively, the instrument is availabl...
Dual-bay Dyad thermal cycler chassis from Bio-Rad
Artisan™ Wash Solution (x 50) from Dako
...Secondary Detection System is intended for use wit...ody reagents, which contain rat and goat IgG for t... microscopy in paraffin-embedded tissues. The IHC ...m may also be used with other rat or goat primary ...
Biology Products: